Fiche société
Autolus Limited
Traitements, essais et publications liés.
Traitements4programmes
Essais2liés
Publications4liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Obecabtagene autoleucelThe purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN). | Lupus | Phase 2 | À vérifier | United States, Brazil, Greece, United Kingdom, Vietnam | À vérifier |
| Obecabtagene autoleucel (obe-cel)This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE. | Lupus | Phase 1 | Immunomodulation | Spain, United Kingdom | À vérifier |
| Obecabtagene autoleucel (obe-cel)This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE. | Lupus | Phase 1 | Immunomodulation | Spain, United Kingdom | À vérifier |
| Obecabtagene autoleucelThe purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN). | Lupus | Phase 2 | À vérifier | United States, Brazil, Greece, United Kingdom, Vietnam | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Obecabtagene autoleucel | Lupus | Phase 2 | NCT07053800 | LUMINA — Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | RECRUITING |
| Obecabtagene autoleucel (obe-cel) | Lupus | Phase 1 | NCT06333483 | CARLYSLE — Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
Publications
4| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Obecabtagene autoleucel | Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. | Japanese journal of clinical oncology | ||
| Obecabtagene autoleucel (obe-cel) | CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. | Cancer research communications | ||
| Obecabtagene autoleucel (obe-cel) | Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. | Leukemia | ||
| Obecabtagene autoleucel (obe-cel) | Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. | The Annals of pharmacotherapy |